Investment Rating - The report maintains a "Buy" rating for the company [3][6]. Core Views - The company's electrophysiology and vascular intervention businesses continue to grow rapidly, meeting expectations [3]. - The forecasted EPS for 2024-2026 is set at 7.13, 9.75, and 12.90 CNY respectively, with a target price raised to 434.88 CNY from 342.66 CNY [3][6]. - The company achieved a revenue of 1 billion CNY in H1 2024, representing a year-on-year increase of 27.0%, and a net profit of 343 million CNY, up 33.1% [3]. Summary by Sections Financial Performance - In H1 2024, the company reported revenue of 1 billion CNY, with a net profit of 343 million CNY and a non-GAAP net profit of 328 million CNY, reflecting increases of 27.0%, 33.1%, and 35.2% respectively [3]. - For Q2 2024, the company recorded a revenue of 546 million CNY, a 24.5% increase year-on-year, and a net profit of 202 million CNY, up 30.8% [3]. Business Segments - The electrophysiology business generated revenue of 223 million CNY in H1 2024, accounting for approximately 22% of total revenue, with significant growth in three-dimensional surgeries [3]. - The coronary access products achieved revenue of 503 million CNY, while peripheral intervention products contributed 175 million CNY in H1 2024, with hospital penetration rates improving significantly [3]. Market Position - The company has expanded its hospital coverage to over 4,000, with a nearly 20% increase in coronary product admissions compared to H1 2023, and over 30% growth in peripheral product admissions [3]. - The company is enhancing its competitive edge in the market through improved product performance and increased production capabilities [3].

——2024 年中报点评 量价齐升，盈利弹性显现 珠江啤酒(002461) 食品饮料 [Table_Industry] /必需消费 | --- | --- | --- | |-----------------------------|-----------|-------| | [Table_Invest] 评级： | | 增持 | | | 上次评级: | 增持 | | [Table_Target] 目标价格： | | 10.05 | | | 上次预测: | 10.05 | | [当前价格： Table_CurPrice] | | 8.48 | | --- | --- | |----------|--------------------| | | 陈力宇(分析师) | | | 021-38677618 | | | chenliyu@gtjas.com | | 登记编号 | S0880522090005 | 本报告导读： 公司 24Q2 持续相对较好的量价表现，吨价明显提升、吨成本显著下降，毛利率实 现大幅改善，相对优势凸显。 投资要点： [Table_Summary] 投资建议：维持"增持"评级。考虑公司吨价 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price adjusted to 17.51 yuan, down from 25.89 yuan [2][6] Core Views - The company reported H1 2024 revenue of 17.654 billion yuan, a decrease of 19.33% YoY, and net profit attributable to shareholders of 2.227 billion yuan, down 57.96% YoY [2] - Q2 2024 revenue was 8.995 billion yuan, down 9.96% YoY, and net profit was 939 million yuan, down 50.99% YoY, both below market expectations [2] - The company's coal production in H1 2024 was 27.67 million tons, a decrease of 6.3% YoY, with commercial coal sales of 24.55 million tons, down 10% YoY [2] - The company's Q2 production recovery was significant, with commercial coal production reaching 14.43 million tons, a decrease of only 3% YoY, compared to a 10% decline in Q1 [2] - The report expects the company's production and sales to return to normal levels in Q3, with sales expected to stabilize or grow [2] Financial Performance - The company's average selling price in H1 2024 was 683 yuan/ton, down 90 yuan/ton YoY, but the price pressure eased in Q2, with the average selling price at 677 yuan/ton, down only 3 yuan/ton YoY [2] - The company's cost per ton increased by 44 yuan/ton YoY in Q2, reaching 365 yuan/ton, which significantly impacted profitability [2] - The company's gross profit per ton in Q2 was 312 yuan/ton, down 46.5 yuan/ton YoY [2] - The report forecasts EPS for 2024-2026 to be 1.67, 2.09, and 2.55 yuan, respectively, with downward revisions of 0.62, 0.50, and 0.37 yuan [2] Industry and Market Context - The company's coal production in Shanxi Province recovered to 114 million tons in June 2024, reaching the 2023 monthly average, indicating a return to normal production levels [2] - The report highlights that the company's production and sales pressure peaked in H1 2024, with expectations of improvement in H2 [2] - The company's resource tax increased in Q2 2024, with the tax rate for raw coal rising from 8% to 10%, and the tax rate for processed coal rising from 6.5% to 9%, leading to an additional tax burden of approximately 250 million yuan per quarter [2] Financial Forecasts - The report forecasts the company's revenue for 2024-2026 to be 37.509 billion, 39.741 billion, and 42.156 billion yuan, respectively, with growth rates of -13.0%, 6.0%, and 6.1% [4] - Net profit attributable to shareholders is expected to be 4.997 billion, 6.248 billion, and 7.629 billion yuan for 2024-2026, with growth rates of -36.9%, 25.0%, and 22.1% [4] - The company's ROE is expected to be 9.9%, 11.7%, and 13.6% for 2024-2026, respectively [4]

——小米集团 2024 年二季度财报 | --- | --- | --- | |----------|---------------------|------------------------| | | 吴晓飞(分析师) | 管正月(分析师) | | | 0755-23976003 | 021-38032026 | | | wuxiaofei@gtjas.com | guanzhengyue@gtjas.com | | 登记编号 | S0880517080003 | S0880521030003 | 本报告导读： 小米集团 2024 年二季度财报单独披露汽车业务，盈利能力继续提升，产能爬坡和渠 道开拓不断推进，全年交付目标提升至 12 万辆，供应链持续受益。 投资要点： [Table_Summary] 投资建议：维持行业增持评级，小米汽车交付不断加速，产能瓶颈 逐步打开，收入和盈利能力持续提升，随着小米汽车产销规模的增 长，相关配套汽车零部件将有望受益，推荐无锡振华、上声电子、 拓普集团、双环传动、银轮股份等。 事件简述：8 月 21 日小米集团公告 2024 年二季度财报，2Q24 实现 收入 889 亿 ...

Investment Rating - The report maintains a rating of "Buy" for the company [2][5]. Core Insights - The company has shown strong performance with a revenue of 1.365 billion yuan in H1 2024, representing a growth of 38.4%, and a net profit of 107 million yuan, up by 15.1% [5]. - The adjusted net profit reached 148 million yuan, marking a significant increase of 45.3% [5]. - The gross margin improved to 29.4%, an increase of 0.7 percentage points, while the adjusted profit margin rose to 10.8%, up by 0.5 percentage points [5]. - The company forecasts adjusted net profits of 399 million, 519 million, and 670 million yuan for 2024, 2025, and 2026, respectively, indicating year-on-year growth rates of 31%, 30%, and 29% [5]. - The target market capitalization is set at 12 billion yuan, with a target price of 48.97 yuan (53.52 HKD) based on a PE ratio of 30X for 2024 [5]. Summary by Sections Performance Overview - The company added 420,000 new customers in H1 2024, a growth of 21.1%, bringing the total customer base to 3.957 million [5]. - The number of customer visits reached 2.383 million, an increase of 31.9%, with a customer retention rate of 69.5%, up by 2.2 percentage points [5]. - Average spending per visit increased to 573 yuan, reflecting a growth of 4.9% [5]. - Membership numbers grew by 49.3% to 261,000, with member visits increasing by 51.1% to 938,000 [5]. Expansion and Market Share - The company is expanding its market presence through both self-built and acquired branches, adding 16 new locations (4 self-built and 12 acquired) [5]. - The company has entered new cities including Singapore, Changsha, Xuzhou, and Changshu, operating a total of 74 stores across 20 cities [5]. - The company has established partnerships with 26 medical alliances, enhancing its doctor resources with over 39,000 practicing physicians [5]. Financial Projections - Revenue projections for the next three years are as follows: 3.029 billion yuan for 2024, 3.925 billion yuan for 2025, and 5.033 billion yuan for 2026, with respective growth rates of 30.2%, 29.6%, and 28.2% [7]. - The adjusted net profit is expected to grow significantly, with projections of 399 million yuan for 2024, 519 million yuan for 2025, and 670 million yuan for 2026 [7].

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Views - The company's performance in the first half of 2024 met expectations, with notable growth in overseas business despite a year-on-year decline in overall profit [2][3] - The company is expected to improve its profitability in the second half of 2024 as production capacity for playing cards increases and new game products are launched [3] Summary by Relevant Sections Financial Performance - For the first half of 2024, the company reported revenue of 1.908 billion yuan, a year-on-year decrease of 18.65%, and a net profit attributable to shareholders of 284 million yuan, down 30.29% [3] - The second quarter of 2024 saw revenue of 927 million yuan, a quarter-on-quarter decline of 5.58% and a year-on-year decline of 19.96% [3] - The company's playing card business remained stable, generating revenue of 491 million yuan, a year-on-year decrease of 4.72% [3] Business Segments - The mobile gaming segment experienced a revenue decline of 27.28%, totaling 513 million yuan, while the digital marketing segment saw a revenue drop of 20.29%, amounting to 879 million yuan [3] - The gross margin for the playing card business improved to 30.45%, an increase of 4.42 percentage points year-on-year [3] Overseas Business Growth - The company's overseas revenue reached 103 million yuan, a significant year-on-year increase of 148.82%, driven by the expansion of its game product line in international markets [3] Future Projections - The report forecasts earnings per share (EPS) for 2024, 2025, and 2026 to be 1.56 yuan, 1.86 yuan, and 2.19 yuan respectively, with a target price of 30.05 yuan based on a 20x price-to-earnings ratio for 2024 [3]

Investment Rating - The report maintains a rating of "Buy" for the company [3][5]. Core Views - The company is experiencing steady growth in both domestic and international markets, with a successful rollout of installations and an increase in the sales proportion of mid-to-large machines, which is driving a positive trend in reagent growth [3]. - The revenue for H1 2024 reached 2.211 billion yuan, representing an 18.54% increase year-on-year, while the net profit attributable to shareholders was 903 million yuan, up 20.42% [3]. - The report forecasts EPS for 2024, 2025, and 2026 to be 2.69 yuan, 3.49 yuan, and 4.55 yuan respectively, with a target price of 79.65 yuan, corresponding to a PE of 30X for 2024 [3]. Financial Summary - H1 2024 revenue breakdown: Reagent revenue was 1.591 billion yuan (+21.13%), and instrument revenue was 615 million yuan (+12.40%) [3]. - The gross margin for reagents was 88.50% (down 0.41 percentage points), while the gross margin for instruments improved to 32.11% (up 2.46 percentage points) [3]. - Domestic revenue for H1 2024 was 1.410 billion yuan (+16.30%), with a significant increase in the number of large medical terminal customers [3]. - International revenue for H1 2024 was 796 million yuan (+22.79%), with a notable increase in the sales of mid-to-large instruments [3]. Market Performance - The company has successfully expanded its domestic market share, with a 75.13% installation rate for large machines in H1 2024 [3]. - The overseas market is also showing promising growth, with reagent revenue increasing by 29.11% year-on-year in H1 2024 [3]. - The total market capitalization is approximately 49.445 billion yuan, with a current price of 62.93 yuan [6].

Investment Rating - The report maintains an "Accumulate" rating for AIA Group Limited (1299) [1] Core Views - The report highlights strong growth in New Business Value (NBV) and sets an operational profit target for the next three years that exceeds expectations [2][4] - The current price of the stock is HKD 51.40, with a target price of HKD 89.80 per share, corresponding to a 2024 P/EV of 1.81 times [3][11] Summary by Sections Financial Performance - For the first half of 2024, the net profit attributable to shareholders increased by 47.3% (actual rate) / 53% (fixed rate), meeting expectations [11] - The after-tax operating profit grew by 3.5% (actual rate) / 7% (fixed rate) [11] - The embedded value increased by 1.2% compared to the end of the previous year, primarily due to currency fluctuations and dividends [11] New Business Value (NBV) - The NBV for the first half of 2024 grew by 21% (actual rate) / 25% (fixed rate), exceeding expectations [11] - In Q2, the NBV growth rate was 5.6% (actual rate), showing a slowdown compared to Q1, attributed to a high base from the previous year [11] - Regionally, NBV growth in Hong Kong was 26%, driven by local customers and mainland visitors [11] - In mainland China, NBV growth reached 36%, with new branches contributing significantly [11] Operational Targets - Management has set a three-year target for compound growth in operating profit per share of 9%-11% from 2023 to 2026 [11] - This growth is expected to be driven by contributions from new business profitability and effective management of existing business [11] Dividend Policy - The interim dividend for 2024 is set at HKD 0.445 per share, a year-on-year increase of 5.2%, with a payout ratio of 50.4% [11]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company is adjusting its profit expectations due to a weakening downstream consumption environment and intensified market price competition. The expected EPS for 2024-2026 is revised to 0.90, 1.16, and 1.41 yuan, respectively, down from previous estimates of 1.06, 1.36, and 1.66 yuan. The target price is adjusted to 31.94 yuan, with a PE ratio of 35.5x for 2024 [4][5] - The core product growth remains resilient, with the lens business experiencing a 14.0% year-on-year increase in H1 2024, driven by a focus on product strategy. The PMC Ultra Bright series saw a revenue increase of 59% year-on-year in H1 2024 [4] - The profit margin continues to benefit from product mix optimization, with a gross margin of 60.7% in Q2 2024, up 3.6 percentage points year-on-year [4] Summary by Sections Company Overview - The company is focused on brand positioning and product iteration to stabilize pricing amidst fierce external competition [3] Financial Performance - The company reported a revenue of 767 million yuan for 2024E, with a growth rate of 2.5% compared to 2023. The net profit attributable to the parent company is expected to be 181 million yuan, reflecting a growth of 15.1% [9][10] Strategic Initiatives - The company has established a unique partnership with Leica in April 2024 to expand its presence in the high-end market. It continues to innovate with product iterations and has launched the "Easy Control Pro 2.0" in August 2024 [4] - The company is also enhancing its channel strategy, with a focus on large and medium-sized clients, and has seen over 40% growth in medical channels in H1 2024 [4] Market Position - The company’s stock has a current price of 25.06 yuan, with a target price of 31.94 yuan, indicating potential upside [5][6]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company's performance in the first half of 2024 was slightly below expectations, with revenue of 57.005 billion yuan, a year-on-year decrease of 2.26%, and a net profit attributable to shareholders of 2.725 billion yuan, down 10.34% year-on-year [1][3] - The company has adjusted its net profit forecasts for 2024-2026 to 5.854 billion, 6.148 billion, and 6.329 billion yuan respectively, down from previous estimates [1] - The target price has been lowered to 13.92 yuan from 19.41 yuan, based on a 12x PE valuation for 2024 [1][5] Financial Summary - Revenue for 2022 was 98.345 billion yuan, with a projected increase to 114.930 billion yuan in 2024, reflecting a growth of 0.8% [2] - The net profit attributable to shareholders is expected to decrease from 7.105 billion yuan in 2022 to 5.854 billion yuan in 2024, indicating a decline of 2.3% [2] - The earnings per share (EPS) is projected to be 1.16 yuan in 2024, slightly down from 1.41 yuan in 2022 [2] Sales Performance - In the first half of 2024, the company achieved sales volumes of 4.8 million tons and 4.72 million tons in Q1 and Q2 respectively, totaling 9.52 million tons, an increase of 100,000 tons year-on-year [1] - The average selling prices for the first two quarters were 5,923 yuan and 6,060 yuan per ton, with gross margins of 729 yuan and 746 yuan per ton [1] Product Structure Adjustment - The company is actively adjusting its product mix to capture market opportunities, with bearing steel sales exceeding 1 million tons, up 13.04% year-on-year, and automotive steel sales exceeding 3 million tons, up 13.12% year-on-year [1] - The sales of "two highs and one special" products increased by 24% year-on-year [1] Innovation and Cost Management - The company continues to invest in R&D, achieving significant breakthroughs in high-temperature alloy materials, with over 30 model certifications from Chinese aviation manufacturers [1] - The company has improved key production and technical indicators by 73% year-on-year, focusing on reducing financing and operational costs [1]